Emicizumab in two patients with acquired haemophilia A – case report
Patients with acquired haemophilia A (PwAHA) can present with severe bleeding and may require lengthy treatment with bypassing agents and immunosuppression. We present two cases of the implementation of emicizumab in PwAHA. The first patient, an 82-year-old man with rheumatoid arthritis (RA), presen...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2024-08-01
|
| Series: | The Journal of Haemophilia Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/jhp-2024-0016 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832570297200410624 |
|---|---|
| author | Zhao Milly Kartika Thomas Witenko Corey Snead Jessica DeSancho Maria T Ciolek Alana |
| author_facet | Zhao Milly Kartika Thomas Witenko Corey Snead Jessica DeSancho Maria T Ciolek Alana |
| author_sort | Zhao Milly |
| collection | DOAJ |
| description | Patients with acquired haemophilia A (PwAHA) can present with severe bleeding and may require lengthy treatment with bypassing agents and immunosuppression. We present two cases of the implementation of emicizumab in PwAHA. The first patient, an 82-year-old man with rheumatoid arthritis (RA), presented with acquired haemophilia A (AHA) and spontaneous left tibia hematoma complicated by a persistent wound and infections. After a month of intermittent bleeding at the site and immunosuppression, the inhibitor level remained elevated and he was placed on emicizumab. While on therapy, debridement of the wound required activated factor VII therapy, which was complicated by a venous thromboembolism (VTE). He was successfully managed with anticoagulation while on emicizumab until his inhibitor level was undetectable. The second patient is a 62-year-old woman, also with RA and with a persistently positive dilute Russell viper venom time who presented with intracerebral haemorrhage (ICH) and was found to have AHA. After a period of time on bypassing agents, emicizumab was started due to a persistent inhibitor level and the ICH remained stable. She only required two doses initially, however, had a relapse with recurrent factor VIII inhibitor and received three additional doses without any complications. These cases highlight that emicizumab is a viable option in the care of PwAHA in challenging scenarios such as in the context of VTE and ICH. |
| format | Article |
| id | doaj-art-421bc4fc750a4b3db7ed635b111b9b85 |
| institution | Kabale University |
| issn | 2055-3390 |
| language | English |
| publishDate | 2024-08-01 |
| publisher | Sciendo |
| record_format | Article |
| series | The Journal of Haemophilia Practice |
| spelling | doaj-art-421bc4fc750a4b3db7ed635b111b9b852025-02-02T15:48:30ZengSciendoThe Journal of Haemophilia Practice2055-33902024-08-01111929810.2478/jhp-2024-0016Emicizumab in two patients with acquired haemophilia A – case reportZhao Milly0Kartika Thomas1Witenko Corey2Snead Jessica3DeSancho Maria T4Ciolek Alana5Department of Pharmacy, New York-Presbyterian/Weill Cornell Medical Center, New York, NY, USADivision of Hematology and Medical Oncology, Department of Medicine, New York-Presbyterian/Weill Cornell Medical Center, New York, NY, USADepartment of Pharmacy, New York-Presbyterian/Weill Cornell Medical Center, New York, NY, USADepartment of Pharmacy, New York University Langone Health, Brooklyn, NY, USADivision of Hematology and Medical Oncology, Department of Medicine, New York-Presbyterian/Weill Cornell Medical Center, New York, NY, USADepartment of Pharmacy, New York-Presbyterian/Weill Cornell Medical Center, New York, NY, USAPatients with acquired haemophilia A (PwAHA) can present with severe bleeding and may require lengthy treatment with bypassing agents and immunosuppression. We present two cases of the implementation of emicizumab in PwAHA. The first patient, an 82-year-old man with rheumatoid arthritis (RA), presented with acquired haemophilia A (AHA) and spontaneous left tibia hematoma complicated by a persistent wound and infections. After a month of intermittent bleeding at the site and immunosuppression, the inhibitor level remained elevated and he was placed on emicizumab. While on therapy, debridement of the wound required activated factor VII therapy, which was complicated by a venous thromboembolism (VTE). He was successfully managed with anticoagulation while on emicizumab until his inhibitor level was undetectable. The second patient is a 62-year-old woman, also with RA and with a persistently positive dilute Russell viper venom time who presented with intracerebral haemorrhage (ICH) and was found to have AHA. After a period of time on bypassing agents, emicizumab was started due to a persistent inhibitor level and the ICH remained stable. She only required two doses initially, however, had a relapse with recurrent factor VIII inhibitor and received three additional doses without any complications. These cases highlight that emicizumab is a viable option in the care of PwAHA in challenging scenarios such as in the context of VTE and ICH.https://doi.org/10.2478/jhp-2024-0016acquired haemophiliaemicizumabintracranial haemorrhageinhibitorsrecombinant factor viiacase report |
| spellingShingle | Zhao Milly Kartika Thomas Witenko Corey Snead Jessica DeSancho Maria T Ciolek Alana Emicizumab in two patients with acquired haemophilia A – case report The Journal of Haemophilia Practice acquired haemophilia emicizumab intracranial haemorrhage inhibitors recombinant factor viia case report |
| title | Emicizumab in two patients with acquired haemophilia A – case report |
| title_full | Emicizumab in two patients with acquired haemophilia A – case report |
| title_fullStr | Emicizumab in two patients with acquired haemophilia A – case report |
| title_full_unstemmed | Emicizumab in two patients with acquired haemophilia A – case report |
| title_short | Emicizumab in two patients with acquired haemophilia A – case report |
| title_sort | emicizumab in two patients with acquired haemophilia a case report |
| topic | acquired haemophilia emicizumab intracranial haemorrhage inhibitors recombinant factor viia case report |
| url | https://doi.org/10.2478/jhp-2024-0016 |
| work_keys_str_mv | AT zhaomilly emicizumabintwopatientswithacquiredhaemophiliaacasereport AT kartikathomas emicizumabintwopatientswithacquiredhaemophiliaacasereport AT witenkocorey emicizumabintwopatientswithacquiredhaemophiliaacasereport AT sneadjessica emicizumabintwopatientswithacquiredhaemophiliaacasereport AT desanchomariat emicizumabintwopatientswithacquiredhaemophiliaacasereport AT ciolekalana emicizumabintwopatientswithacquiredhaemophiliaacasereport |